Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations

Immunovant CEO Peter Salzmann sold shares of common stock on January 15, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On January 15, 2025, Peter Salzmann, the CEO of Immunovant, Inc., sold shares of Immunovant's common stock.
• A total of 8,767 shares were sold in two separate transactions.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on April 12, 2023.
• The sales were mandated by the issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.
• Following the transactions, Salzmann directly owns 964,225 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. The CEO sold shares to cover taxes, which is a normal occurrence and doesn't necessarily reflect a positive or negative outlook on the company.

Industry Context

Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. This filing indicates that the CEO sold shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The sale of shares by the CEO could have a minor, temporary impact on the stock price, but it is unlikely to be significant given the reason for the sale.

Key Dates